Historically, endpoints in oncology clinical trials centered on tumor response, but this approach alone fails to take into account how well a treatment is tolerated or how patients cope with their symptoms.
More recently, industry and regulatory bodies increasingly incorporate patient-reported outcomes to measure soft endpoints.
In this article, we explore the value of PROs to clinical trials and outline important considerations for incorporating them into oncology trials.
